Therefore, reducing the expression of PNPLA3 148M in HSCs in addition to hepatocytes is expected to provide a multi-faceted therapeutic benefit for NASH patients. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.